Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Stock pick for 2024: Adobe is one of the best ways to play AI

It may look like odd timing to back Adobe (ADBE:NASDAQ) just after lukewarm guidance, but we think this is a great opportunity.
The creative digital software firm called for fiscal 2024 earnings per share of $17.60 to $18 on $21.3 billion to $21.5 billion revenue, a little light compared with the consensus of $18 and $21.7 billion revenue respectively.
The shares plunged 7%, which seemed harsh to us for a bit of near-term uncertainty, especially given the proven quality of this business. We still strongly believe that Adobe stands out for several clear reasons: its consistently strong financial performance; a powerful balance sheet; exposure to structurally growing markets; and as a great play on AI, or artificial intelligence.
Adobe’s 2024 price to earnings multiple is 32.5, falling below 28 and 25 over the following couple of years as earnings per share close on $24 forecasts. This still might not look especially cheap to many investors, but it is historically low for a business consistently growing way above market averages and delivering 34% operating margins and return on equity. Return on capital employed is 30.9%.
At the end of 2023, Adobe could be sitting on more than $3 billion of net cash. This business is a giant in the creative software space through tools like PDFs, Photoshop, Illustrator, InDesign and Premiere Pro. It is reckoned to own a rough 50% market share. AI is now becoming Adobe’s growth secret sauce, and it has already integrated Firefly into the toolkit, designed to help creatives be more creative.
Ben Rogoff, manager of the Polar Capital Global Technology (B42W4J8) fund and Polar Capital Technology Trust (PCT) has recently admitted bolstering his Adobe positions because its scope to monetise AI is one of the best around.
Adobe’s $20 billion acquisition of rival Figma has been canned after facing regulatory hell. While something of a blow it at least provides a measure of clarity and we believe the company retains its long-run appeal for investors regardless.
To date, 2023 has seen the stock rally more than 70%, tilting the volatility needle, which may not suit every investor. That said, with interest rates looking increasingly like falling in 2024, the market backcloth should be healthier for growth stocks next year.
Analyst consensus has a $700 stock valuation for the next year, and we wouldn’t be at all surprised to see the stock top that in 2024.
Disclaimer: The author of the article (Steven Frazer) owns a personal stake in Polar Capital Technology Trust.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Case study
Feature
- Return from our 2023 share picks is more than four times that of the UK market
- The best and worst emerging markets in 2023
- Can electricals leader Currys deliver some turnaround spark?
- Discover the stocks the professionals changed their minds on in 2023
- Emerging markets: China property fixes and dollar weakness
Great Ideas
- 10 stocks for 2024: our best ideas for the year ahead
- Stock pick for 2024: Adobe is one of the best ways to play AI
- Stock pick for 2024: Buy Smith & Nephew for continued recovery and re-rating potential
- Stock pick for 2024: Buy Puretech Health for lower risk access to an exciting drug portfolio
- Stock pick for 2024: MongoDB is one of the hottest software plays on AI
- Stock pick for 2024: B&M's growth ambitions and value focus make it a compelling story
- Stock pick for 2024: Hunting is attractively priced and evidence of transformation is a clear catalyst
- Stock pick for 2024: The market has not spotted RELX for the AI winner it is
- Stock pick for 2024: Just Group is so cheap and has big growth drivers behind it
- Stock pick for 2024: Hollywood Bowl is a strikingly resilient operator trading at the wrong price
- Stock pick for 2024: Take advantage of this 'generational opportunity' to buy Conduit
Investment Trusts
News
- How TSMC could set the New Year tone for tech
- Markets higher despite mixed rates messaging and what to expect from retailers
- Discover the most unloved and most-shorted UK stocks
- Costco climbs to all-time high as members clamour for cheap essentials
- A big acquisition and a slowdown in its largest market have unnerved investors in Rentokil
- UK housebuilders Taylor Wimpey and Persimmon have moved-up strongly